{"id":1017926,"date":"2026-11-05T18:21:52","date_gmt":"2026-11-05T23:21:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/"},"modified":"2026-11-05T18:21:52","modified_gmt":"2026-11-05T23:21:52","slug":"sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/","title":{"rendered":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization"},"content":{"rendered":"
\n

\n Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies<\/i>\n <\/p>\n

\n SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc.<\/b> (NASDAQ: SINT) (\u201cSINTX\u201d or the \u201cCompany\u201d), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026.<\/p>\n

\n Third Quarter Financial Results<\/b>\n <\/p>\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u25cf<\/td>\nFor the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nGross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with gross margin increasing to approximately 62% from 45% reflecting improved pricing, higher manufacturing volumes, and increased production efficiencies<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nTotal operating expenses decreased 13% to $3.0 million, compared with $3.4 million in the third quarter of 2025<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nNet loss decreased 55% to approximately $1.6 million, compared with $3.5 million during the prior-year quarter<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nOperating loss decreased 51% to $1.6 million, compared with $3.4 million in the third quarter of 2025<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nFor the nine months ended September 30, 2026, total revenue increased 315% to approximately $3.0 million<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nSINTX ended the third quarter with approximately $2.0 million in cash and cash equivalents and subsequently received approximately $2.0 million in gross proceeds from the exercise of Class B warrants. The Company continues to pursue revenue growth, operating efficiencies, and additional financing alternatives to support operations and commercialization activities.<\/td>\n<\/tr>\n<\/table>\n

\n
\u201cOur third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies,\u201d said Eric Olson, Chief Executive Officer of SINTX.<\/p>\n

\u201cThe substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities. Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare.<\/p>\n

\u201cWith the initial commercial sales of our SiNAPTIC\u00ae<\/sup> Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market. We also continue to evaluate opportunities to leverage our proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications.<\/p>\n

\u201cWe believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company. With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027,\u201d concluded Mr. Olson.<\/p>\n

\n Third Quarter and Subsequent 2026 Highlights<\/b>\n <\/p>\n\n\n\n\n\n\n
\u00a0<\/td>\n\u25cf<\/td>\nCompleted the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nSponsored silicon nitride masterclass with leading orthopedics experts in implant retrieval, biomaterials and clinical practice, to help educate surgeons, develop sales channels and build a disciplined commercial foundation<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nRegained compliance with Nasdaq\u2019s minimum stockholders\u2019 equity requirement of $2.5 million<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nReceived aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants at $2.14 per share following the Company\u2019s post-quarter-end call, which was triggered by achieving the third-quarter revenue milestone of $2 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nInitiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties. The studies are expected to be completed in the first quarter of 2027 and are intended to support further preclinical development of potential wound care applications.<\/td>\n<\/tr>\n<\/table>\n

\n
The Company will host a conference call and webcast today at 4:30 p.m. ET to review the Company\u2019s third quarter 2026 performance. Management participants will include Eric Olson, Chief Executive Officer and Chairman of the Board, and Kevin Trask, Chief Financial Officer.<\/p>\n

Interested parties may access the conference call and webcast as follows:<\/p>\n

Webcast: The live webcast will be available on the Events & Presentations<\/a> page of the Company\u2019s investor relations website at investors.sintx.com<\/a> and may also be accessed directly here<\/a>.<\/p>\n

Telephone: Analysts and other participants who wish to join by telephone should register in advance using the Conference Call Registration link<\/a>. Upon registration, participants will receive the dial-in information and a unique PIN.<\/p>\n

A replay of the webcast will be available following the call on the Events & Presentations page of the Company\u2019s investor relations website.<\/p>\n

\n About SINTX Technologies, Inc.<\/b>\n <\/p>\n

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for medical and other specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC\u00ae<\/sup> Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY\u2122<\/sup> technology platform being developed for biocomposite and 3D printing applications.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cwill\u201d and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements include statements regarding continued commercialization and market adoption of its SiNAPTIC\u00ae<\/sup> Foot & Ankle Osteotomy Wedge System; opportunities to leverage its proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications; the anticipated completion, results, and potential applications of ongoing preclinical animal studies evaluating silicon nitride-treated medical textiles for wound care; and advancing specialized medical technologies utilizing its proprietary silicon nitride platform. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. These statements are subject to inherent risks, uncertainties and changes in circumstances that could cause actual results to differ materially from those contemplated or implied by such statements. These risks and uncertainties include the timing and volume of customer orders and product shipments; customer concentration and the potential loss or reduction of business from significant customers; the Company\u2019s ability to maintain or improve manufacturing efficiencies, pricing, and gross margins; uncertainties regarding the timing, completion, and results of preclinical studies; the Company\u2019s ability to secure and execute licensing partnerships; to obtain applicable regulatory clearances or approvals; to protect and enforce its intellectual property; to manufacture products at commercial scale; to obtain sufficient funding; to achieve market acceptance; and to continue as a going concern. Additional risks and uncertainties are described in the Company\u2019s filings with the U.S. Securities and Exchange Commission, including under \u201cRisk Factors\u201d in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law, and readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release.<\/p>\n

\n Company Contact: <\/b>\n <\/p>\n

Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com<\/a><\/p>\n

\n SINTX Technologies, Inc.<\/b>
\n
\n Condensed Consolidated Balance Sheets \u2013 Unaudited<\/b>
\n
\n (in thousands, except share and per-share amounts)<\/b>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\n September 30,<\/b>
\n
\n 2026<\/b>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\n December 31,<\/b>
\n
\n 2025<\/b>\n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Assets<\/b>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Current assets:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Cash and cash equivalents<\/td>\n\u00a0<\/td>\n$<\/td>\n2,005<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n4,140<\/td>\n\u00a0<\/td>\n<\/tr>\n
Accounts and other receivables, net of allowance for credit losses of $2.0 and $2.4 respectively<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n131<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n178<\/td>\n\u00a0<\/td>\n<\/tr>\n
Prepaid expenses and other current assets<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n829<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n507<\/td>\n\u00a0<\/td>\n<\/tr>\n
Inventories<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,555<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n825<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total current assets<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,520<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,650<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Inventories<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n219<\/td>\n\u00a0<\/td>\n<\/tr>\n
Property and equipment, net<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n518<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n476<\/td>\n\u00a0<\/td>\n<\/tr>\n
Intangible assets, net<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n116<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n142<\/td>\n\u00a0<\/td>\n<\/tr>\n
Goodwill<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n302<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n302<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating lease right of use asset<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,213<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,458<\/td>\n\u00a0<\/td>\n<\/tr>\n
Other long-term assets<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n234<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n259<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total assets<\/td>\n\u00a0<\/td>\n$<\/td>\n8,903<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n9,506<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Liabilities and Stockholders\u2019 Equity<\/b>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Current liabilities:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Accounts payable<\/td>\n\u00a0<\/td>\n$<\/td>\n961<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n382<\/td>\n\u00a0<\/td>\n<\/tr>\n
Accrued liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,190<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n422<\/td>\n\u00a0<\/td>\n<\/tr>\n
Debt<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n55<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n7<\/td>\n\u00a0<\/td>\n<\/tr>\n
Derivative liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n345<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n827<\/td>\n\u00a0<\/td>\n<\/tr>\n
Current portion of operating lease liability<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n440<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n398<\/td>\n\u00a0<\/td>\n<\/tr>\n
Other current liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n13<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,697<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total current liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,004<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,733<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating lease liability, net of current portion<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,509<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,844<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,513<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n6,577<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Commitments and contingencies<\/b>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n \u00a0<\/b>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Stockholders\u2019 equity:<\/b>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Convertible preferred stock Series B, C, D, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 249 total preferred shares issued and outstanding as of September 30, 2026 and December 31, 2025.<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Common stock, $0.01 par value, 250,000,000 shares authorized; 6,937,357 and 4,021,293 shares issued and 6,886,933 and 3,970,869 outstanding as of September 30, 2026 and December 31, 2025, respectively.<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n69<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n40<\/td>\n\u00a0<\/td>\n<\/tr>\n
Treasury Stock, 50,424 shares as of September 30, 2026 and December 31, 2025.<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(133<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(133<\/td>\n)<\/td>\n<\/tr>\n
Additional paid-in capital<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n302,678<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n295,124<\/td>\n\u00a0<\/td>\n<\/tr>\n
Accumulated deficit<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(299,224<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(292,102<\/td>\n)<\/td>\n<\/tr>\n
Total stockholders\u2019 equity<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,390<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,929<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total liabilities and stockholders\u2019 equity<\/td>\n\u00a0<\/td>\n$<\/td>\n8,903<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n9,506<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n
SINTX Technologies, Inc.<\/b>
\n
\n Condensed Consolidated Statements of Operations \u2013 Unaudited<\/b>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\n Three Months Ended<\/b>
\n
\n September 30,<\/b>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\n Nine Months Ended<\/b>
\n
\n September 30,<\/b>\n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n \u00a0<\/b>\n <\/td>\n\n 2026<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n 2025<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n 2026<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n\n 2025<\/b>\n <\/td>\n\n \u00a0<\/b>\n <\/td>\n<\/tr>\n
Product revenue<\/td>\n\u00a0<\/td>\n$<\/td>\n2,090<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n150<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n2,837<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n541<\/td>\n\u00a0<\/td>\n<\/tr>\n
Grant and contract revenue<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n100<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n58<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n185<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n187<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total revenue<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,190<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n208<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,022<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n728<\/td>\n\u00a0<\/td>\n<\/tr>\n
Costs of revenue<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n828<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n115<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,238<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n455<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross profit<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,362<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n93<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,784<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n273<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating expenses:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Research and development<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n548<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,264<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,485<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,618<\/td>\n\u00a0<\/td>\n<\/tr>\n
General and administrative<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,251<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,102<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n7,104<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n4,836<\/td>\n\u00a0<\/td>\n<\/tr>\n
Sales and marketing<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n140<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n59<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n812<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n100<\/td>\n\u00a0<\/td>\n<\/tr>\n
Grant and contract expenses<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n58<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n23<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n113<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n122<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total operating expenses<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,997<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,448<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n9,514<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n8,676<\/td>\n\u00a0<\/td>\n<\/tr>\n
Loss from operations<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(1,635<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(3,355<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(7,730<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(8,403<\/td>\n)<\/td>\n<\/tr>\n
Other income (expenses):<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Interest expense<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(2<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(13<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(16<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(40<\/td>\n)<\/td>\n<\/tr>\n
Interest income<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n11<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n43<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n45<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n130<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gain on disposal of equipment<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n327<\/td>\n\u00a0<\/td>\n<\/tr>\n
Change in fair value of derivative liabilities<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(214<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n482<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(166<\/td>\n)<\/td>\n<\/tr>\n
Other income, net<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n31<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n97<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total other income (expense), net<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n40<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(184<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n608<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n254<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss before income taxes<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(1,595<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(3,539<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(7,122<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(8,149<\/td>\n)<\/td>\n<\/tr>\n
Provision for income taxes<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(1,595<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,539<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(7,122<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(8,149<\/td>\n)<\/td>\n<\/tr>\n
Deemed dividend \u2013 warrant modification<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(926<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n<\/tr>\n
Deemed dividend \u2013 warrant inducement<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(6,719<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n–<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(6,719<\/td>\n)<\/td>\n<\/tr>\n
Net loss attributable to common stockholders<\/td>\n\u00a0<\/td>\n$<\/td>\n(1,595<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(10,258<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(8,048<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(14,868<\/td>\n)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss per share \u2013 basic and diluted<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Basic \u2013 net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.24<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.19<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.37<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3.38<\/td>\n)<\/td>\n<\/tr>\n
Basic \u2013 attributable to common stockholders<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.24<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3.46<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.55<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(6.17<\/td>\n)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted \u2013 net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.24<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.19<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.37<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3.38<\/td>\n)<\/td>\n<\/tr>\n
Diluted \u2013 attributable to common stockholders<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.24<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3.46<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.55<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(6.17<\/td>\n)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Weighted average common shares outstanding:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Basic<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n6,665,926<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,963,539<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,186,059<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,411,004<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n6,665,926<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,963,539<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,186,570<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,411,179<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (\u201cSINTX\u201d or the \u201cCompany\u201d), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter Financial Results \u00a0 \u25cf For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period \u00a0 \u25cf Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with … <\/p>\n

Continue reading “SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017926","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (\u201cSINTX\u201d or the \u201cCompany\u201d), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter Financial Results \u00a0 \u25cf For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period \u00a0 \u25cf Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with … Continue reading "SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T23:21:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization\",\"datePublished\":\"2026-11-05T23:21:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/\"},\"wordCount\":1547,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/\",\"name\":\"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=\",\"datePublished\":\"2026-11-05T23:21:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/","og_locale":"en_US","og_type":"article","og_title":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk","og_description":"Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (\u201cSINTX\u201d or the \u201cCompany\u201d), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter Financial Results \u00a0 \u25cf For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period \u00a0 \u25cf Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with … Continue reading \"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T23:21:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization","datePublished":"2026-11-05T23:21:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/"},"wordCount":1547,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/","name":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=","datePublished":"2026-11-05T23:21:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTY3OCM3OTQ5Nzc5IzIwMTc1MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sintx-reports-record-third-quarter-2026-revenue-growth-and-advances-medical-device-commercialization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017926"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017926\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}